Boehringer Ingelheim, MD Anderson Cancer Center partner to discover new medicines for pancreatic cancer
The new collaboration combines MD Anderson’s unique understanding of potential drivers of PDAC with Boehringer Ingelheim’s experience in drug discovery and development. Pancreatic cancer accounts for four percent